What is Lab24?
Based in Redding, California, Lab24 operates as a licensed and accredited reference laboratory, serving as a critical node in the regional healthcare infrastructure. The firm specializes in a comprehensive suite of diagnostic services, including urine and oral fluid toxicology, alongside advanced molecular PCR testing. By prioritizing local processing, Lab24 effectively reduces turnaround times for a diverse clientele, ranging from primary-care practices and behavioral-health clinics to pain management specialists and telehealth providers. Their commitment to technological integration ensures that clinical decision-making is supported by high-fidelity data, positioning the company as a reliable partner for both individual patients and institutional healthcare providers.
How much funding has Lab24 raised?
Lab24 has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Lab24
PPP
Public-Private Partnership
What's next for Lab24?
The infusion of capital signals a transition toward scaling operations and potentially broadening the scope of their diagnostic capabilities. As the company navigates this late-stage growth phase, the focus will likely shift toward optimizing laboratory throughput and enhancing the digital integration of their testing services for telehealth partners. By leveraging this strategic investment, Lab24 is poised to solidify its market share in the toxicology and molecular diagnostics sector, ensuring that its infrastructure remains resilient against the evolving demands of modern clinical environments. Future initiatives may include the adoption of next-generation sequencing technologies or the expansion of their service network to accommodate the increasing volume of court-mandated and employer-based testing programs.
See full Lab24 company page
